|
" Cytokines in hemopoiesis, oncology, and AIDS "
M. Freund, H. Link, K. Welte, eds.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
727807
|
| Doc. No
|
:
|
b547543
|
| Main Entry
|
:
|
M. Freund, H. Link, K. Welte, eds.
|
| Title & Author
|
:
|
Cytokines in hemopoiesis, oncology, and AIDS\ M. Freund, H. Link, K. Welte, eds.
|
| Publication Statement
|
:
|
Berlin ; New York: Springer-Verlag, ©1990.
|
| Page. NO
|
:
|
lvii, 762 pages : illustrations ; 24 cm
|
| ISBN
|
:
|
0387522816
|
|
|
:
|
: 3540522816
|
|
|
:
|
: 9780387522814
|
|
|
:
|
: 9783540522812
|
| Notes
|
:
|
Based on a symposium held June 14-17, 1989, in Hannover, Germany, the first of the international symposia on cytokines in hemopoiesis, oncology, and AIDS.
|
| Contents
|
:
|
Overview.- Colony Stimulating Factors:Past and Future.- Regulation of Hematopoietic Progenitor Cell Growth by Stimulating and Suppressing Cytokines.- Cytokine Interactions in Normal and Malignant Hematopoiesis.- Preclinical and In Vitro Data.- Colony Stimulating Factors in Normal Hematopoiesis.- Screening the Sensitivity of Hematopoietic Progenitor Cells to Different Growth Factors. Potential Importance in Therapy Trials with Colony Stimulating Factors.- Effect of Human Recombinant Interleukin-3 in Long-term Bone Marrow Culture.- Secretion of Colony-Stimulating Factor for Macrophages (M-CSF) and Granulocyte/Macrophages (GM-CSF) is Developmentally Regulated in Human Macrophages.- Expression of the M-CSF/CSF-1 Gene in Normal Human Alveolar Macrophages.- Surface Expression of Interleukin-2 Receptors and CD4 Molecules by Human Eosinophils is Induced by GM-CSF and IL-3.- Expression of Interleukin Receptors on Human Eosinophils, Basophils, and Mast Cells.- Chemiluminescene of Polymorphonuclear Leukocytes in Response to Interferons.- Glycolysis and Amino Acid Incorporation in IL-3-Dependent Cell Lines.- Fibroblast Colony Stimulating Activity of GM-CSF and IL-3 in Human Bone Marrow Cell Cultures.- Chromatin and DNA Methylation Changes of the Human Myeloperoxidase Gene During Myeloid Differentiation.- Retroviral-Mediated Transfer of Genes Encoding for Growth Factors into Human Hematopoietic Stem Cells.- Colony Stimulating Factors in Malignant Hematopoiesis.- Recruitment Therapy in Acute Myeloblasts Leukemia:A Different Approach to Improved Leukemia Treatment.- Effects of Hematopoietic Growth Factors on Myelodysplastic Syndrome Progenitors.- Combined Cytogenetic and Proliferation Studies of GM-CSF- Stimulated Bone Marrow Cells in Myelodysplasia and Acute Leukemia.- Recombinant Haemopoietic Factors (IL-3, IL-4, GM-CSF) Fail to Induce the Expression of Leucocyte Adhesion Receptors on Leukaemia Myeloid Colonies.- In Vitro Evaluation of Antiproliferative Activity of CCRF-CEM Supernatant on Lymphoid and Nonlymphoid Leukemic Cells.- TNF-?, IL-6, and Phorbol Ester but Not G-, M-, GM-CSF, IL-3, and IL-4 Induce Monocytic Differentiation and Modulate Expression of C-FOS, C-FMS, and C-MYC in the Human Monoblast Line THP-1.- In Vitro and In Vivo Inhibitory Effects of Interferon ? 2b on CML Granuloerythroid Precursors.- Several Cytokines Do Not Influence Activity of P210BCR-ABL Kinase in K562 Cells.- Colony Stimulating Factors in Nonhematopoietic Cells.- Target Cell Specifity of Hematopoietic Growth Factors.- Growth Factor-Dependent Stimulation of Primary Human Tumor Cells.- Stimulation of Colony Formation of Various Human Carcinoma Cell Lines by rhGM-CSF and rhIL-3.- Effects of Recombinant Cytokines on Clonogenic Cells from Primary Human Tumors.- Tumor Necrosis Factor and Interferon.- Mechanisms of TNF Action:Analysis of Receptor Structure and of Regulatory Circuits Controlling Receptor Expression and TNF-Production.- Synergism of Lymphotoxin and Interferon-? in the Growth Inhibition of Breast Cancer Cell Line MCF-7.- In Vitro Effect of Human Interferon-Gamma on Sister Chromatid Exchange Frequency and Proliferation of Cultured Human Amniotic Fluid Cells.- Tumor Necrosis Factor/Cachectin Production by B-Cell Chronic Lymphocytic Leukemia and Hairy Cell Leukemia Cells.- Interleukin-2.- Activation of Cytolytic Effector Cells.- Regulatory Effect of Recombinant Cytokines on NK Cell Differentiation from Early Marrow Precursors.- Human NK Clones Regulate B-cell Development by Release of IFN-? and TNF-?.- Expression of High Affinity IL-2 Receptors on a Hodgkin Cell Line.- Autologous Antileukemia Cytotoxicity Induced by PBL and BM Culture with rIL-2; Use in Autologous BMT for Inducing GVL?.- Interleukin-2-Induced Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia:Improvement of Cytotoxicity by Combinations of Lymphokines or Cytokines.- Interleukin-2 (IL-2) in Acute Leukemia:In Vitro Studies and Possible Clinical Applications.- Other Effects and Factors.- Interleukin-l-? as a Modulator of Cytotoxic Drug Activity Against Human Cancer Cells.- Biological Properties of Human Interleukin-4.- Interleukin-6 (IL-6)/B Cell Stimulatory Factor 2-Dependent Growth of a Human IGA 2/K-Myeloma Cell Line.- Purification of a Mast Cell Growth-Enhancing Activity (MEA) Derived from a Murine Interleukin-2-Dependent, M1sa-Specific T Cell Line.- Mast Cell Growth-Enhancing Activity (MEA) is a Potent Inducer of Interleukin-6 Production in a Murine Interleukin-3- Dependent Mast Cell Line.- Monocyte-Conditioned Medium Factor as Auto-activation Signal for Monocyte Tumor Cytotoxicity.- A Lymphokine Distinct from IL-2 and IL-4 with Proliferative Activity for a CD4+ T Cell Clone is Preferentially Produced by TH2 Cells.- Leukoregulin Enhancement of Tumor Inhibitory Drug Uptake.- Increased Release of Cytokines from Human Peripheral Blood Mononuclear Cells by the ss-Galactoside-Specific Lectin from Clinically Applied Mistletoe Extract.- In Vitro Immunomodulatory Effects of the Thrombocytic Protein C 24.- Degree of 0- and N-Glycosylation of Lympnokines Released from A 23187-/TPA-Induced Lymphocytes Varies Differently with Culture Time.- Phorbol Myristate Acetate and Calcium Ionophore A23187 Induce Two Waves of Lymphokine mRNA Transcription in Stimulated Human Peripheral Blood Lymphocytes.- Comparison of the Engraftment Promoting Potential of High-Dose Cytostatic Agents in Allogeneic Bone Marrow Transplantation.- Clinical Data.- GM-CSF.- Hematopoietins as Adjuvant Therapy in Cancer Patients.- Effect of Chemotherapy Followed by GM-CSF for Acute Leukemias at Higher Age or After Relapse.- Growth Response of Acute Myeloid Leukemic Blasts to GM-CSF In Vitro and In Vivo-Observations in One Patient.- Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor After Autologous Bone Marrow Transplantation.- Recombinant Human GM-CSF for Large-Scale Collection of Circulating Hematopoietic Progenitors in Cancer Patients Treated with High-Dose Cyclophosphamide.- Recombinant Human Granulocyte-Macrophage Colony-stimulating Factor for the Mobilization of Hemopoietic Progenitors Prior to Autologous Peripheral Blood Stem Cell Transplantation.- G-CSF.- Granulocyte Colony-stimulating Factor:Preclinical and Clinical Effects.- Biology and Clinical Applications of Human Granulocyte Colony-Stimulating Factor.- M-CSF.- In Vivo Evaluations of Recombinant Human Macrophage Colony-stimulating Factor.- Interleukin-3.- The In Vivo Effects of IL-3 and GM-CSF in Primates.- Erythropoietin.- IL-3-Enhanced EPO Effects in Subhuman Primates.- Use of Recombinant Human Erythropoietin after Bone Marrow Transplantation.- The Effect of Erythropoietin on Neutrophil Production from Fetal Hematopoietic Progenitors.- Response of Premature Anemic Infants to Subcutaneous Recombinant Erythropoietin.- Interferons.- Interferon-?2b as Therapy for Untreated and Pretreated Patients with Ph1 Positive Chronic Myelogenous Leukemia.- Interferon-?2b in Chronic Myelogenous Leukemia:Experience with Two Treatment Regimen.- Heterogeneous Progenitor Sensitivity to Various Cytokines in Patients with Myeloproliferative Disorders; Correlation of In Vitro Interferon-? Sensitivity with the Clinical Responsiveness to Recombinant Interferon-?.- Influence of Busulfan or Interferon-? Treatment on CFU-C from Bone Marrow and Peripheral Blood in Patients with CML in Chronic Phase.- Incomplete Stroma Formation by Bone Marrow from Chronic Myeloid Leukemia Patients Treated with Interferon.- Polymerase Chain Reaction for the Detection of Chimeric BCR/ABL mRNA in Patients with Chronic Myelogenous Leukemia (CML)-Detection of Minimal Residual Leukemic Cells After Bone Marrow Transplantation.- Interferon-? in the Treatment of Chronic Myeloproliferative Disorders with Thrombocytosis.- Recombinant Interferon-?, but not Interferon-?, is Effective Therapy for Essential Thrombocythemia.- The Role of Interferon-?2 (IFN-?2) in the Treatment of Low-Grade Non-Hodgkin's Lymphoma.
|
|
|
:
|
Preliminary Results of a Randomized Study:IFN-?2 Plus Chlorambucil Versus Chlorambucil Alone.- T. Chisesi, L. Rancan, G. Capnist, G. Santini, A. Porcellini, R. Sertoli, A. Contu, V. Rizzoli, P. Coser, F. Benedetti.- Evaluation of Myelotoxic Effects in Non-Hodgkin's Lymphomas Treated with Interferon-? and Chlorambucil.- Response of Early Stage B-CLL to Interferon-?:2 Years Experience of a Pilot Study.- Successful Treatment of Angioimmunoblastic Lymphadenopathy (AIL) and B Cell Prolymphocytic Leukemia (B-PLL) with Interferon-?.- Interferon Treatment of Neuroendocrine Gut and Pancreatic Tumors.- Interferon-?2b in Patients with Endocrine Active Tumors.- Recombinant Interferon-?2b in Patients with Advanced Osteosarcoma after Aggressive Chemotherapy.- HIV-Associated Kaposi's Sarcoma Treated with Recombinant Interferon-?2b:Long-term Results.- Acute Effects of Recombinant IFN-? on White Blood Cell Counts and Lymphocyte Subsets in the Peripheral Blood of Cancer Patients.- Tumor Necrosis Factor.- Phase I Clinical Studies of Tumor Necrosis Factor in Patients with Advanced Cancer.- Increase of TNF-? Serum Levels in Major Transplant-Related Complications of Human Bone Marrow Transplantation-Association with Acute Graft-Versus-Host Disease and Activation of Host Macrophages.- Interleukin-2.- IL-2 and Cellular Therapy:Lymphokine-Activated Killer Cells and Tumor-Derived Activated Cells.- Sequential Bolus Administration of rIL-2 (RU 49637) in Treatment of Advanced Solid Malignancies.- rIL-2 Immunotherapy for 19 Children with Advanced Metastatic Neuroblastoma.- Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2-3 Months Post ABMT.- IL-2 Treatment in a Patient with Stage IV Neuroblastoma After Allogeneic Bone Marrow Transplantation.- Regional Adoptive Immunotherapy for Hepatic Metastasis.- Adoptive Immunotherapy with IL-2 in 27 Patients with Metastatic Renal Cell Carcinoma.- Adoptive Immunotherapy of Advanced Cancer with LAK Cells and Different Dosages of Interleukin-2:Analysis of Lymphocyte Subpopulations.- Natural Interleukin-2 plus Lymphokine-Activated Killer Cells in Patients with Advanced Malignancy.- Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells.- Immunological Monitoring of Cancer Patients During a Phase I/II Clinical Trial of Natural Interleukin-2.- Antibodies to Interleukin-2 (IL-2) in Patients:Cross Reactivity with Different IL-2 Species.
|
| Subject
|
:
|
Cancer -- Immunotherapy -- Congresses.
|
| Subject
|
:
|
Cytokines -- Testing -- Congresses.
|
| Subject
|
:
|
Hematopoietic system -- Diseases -- Immunotherapy -- Congresses.
|
| LC Classification
|
:
|
RB45.M474 1990
|
| Added Entry
|
:
|
H Link
|
|
|
:
|
K Welte
|
|
|
:
|
M Freund
|
| |